GSK，Anaptysbio对Jemperli收入进行诉讼
GSK, Anaptysbio sue each other over Jemperli revenue
#Jemperli revenue#royalty business#cancer immunotherapy#Anaptysbio sue#Anaptysbio seeks
生命科学资讯
生物技术与制药领域的最新动态
基因疗法细胞培养基市场主要企业——龙沙公司 - openPR.com
Gene Therapy Cell Culture Media Market By Top Companies-Lonza - openPR.com
#Therapy Cell#Cell Culture#Culture Media#Media Market#Gene Therapy
布鲁克、10x Genomics、PacBio、ICU Medical与登士柏西诺德股价飙升，投资者需知要点——雅虎财经
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
制药业将于2026年迎来酝酿多年的关键“转折点”
Pharma faces a critical ‘turning point’ in 2026, years in the making
#turning point’#health landscape#pricing deals#Pharma faces#pharma shape
(Ai zuò chéng wēi xìng de zuì chū yào fù huì bù gōng gǎn MS)
A brain biotech’s top drug fails against MS
#Contineum Therapeutics#Therapeutics dipped#late Thursday#piqued Johnson#brain biotech
Thermo Fisher Scientific：诊断业务收购及近期股价上涨后的价值评估 - simplywall.st
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains - simplywall.st
#Fisher Scientific#Diagnostics Acquisition#Recent Share#Share Price#Price Gains
周五聚焦——口服SERDs瞄准早期机遇，Agios镰状细胞病药物受挫，Avadel不眠竞价战及其他——FirstWord Pharma
Friday Five — Oral SERDs eye earlier opportunities, Agios' SCD miss, Avadel's not-so-sleepy bidding war…and more - FirstWord Pharma
#Agios' SCD#SCD miss#Oral SERDs#bidding war#earlier opportunities
在RFK Jr.影响下，疫苗接种率下滑，公众疑虑加剧
Under RFK Jr., vaccine use slides while suspicion rises
#vaccine revenue#suspicion rises#flu season#federal health#health officials
瑞士龙沙集团拟以25亿欧元出售部分资产——AKM.RU报道
Swiss Lonza Group plans to sell part of assets for 2.5 billion euros - AKM.RU
#Lonza Group#Swiss Lonza#Group plans#billion euros#sell part
罗氏签署协议，获得Freenome癌症检测在美国以外地区的使用权 - MedTech Dive
Roche inks deal for rights to Freenome cancer tests outside US - MedTech Dive
#Freenome cancer#Roche inks#MedTech Dive#inks deal#cancer tests
Regeneron获两项Eylea批准，加剧与罗氏竞争 - 激烈医药市场动态
Regeneron wins 2 Eylea nods, ramping up competition with Roche - Fierce Pharma
#Eylea nods#Fierce Pharma#Regeneron wins#Roche Fierce#Pharma Regeneron
无头尸骸揭示欧洲首批农民消失之谜
Headless bodies hint at why Europe’s first farmers vanished
#vanished Wave#Headless bodies#pan-European culture#bodies hint#farmers vanished
Saturna Capital Corp持有安捷伦科技公司6300万美元股份，股票代码$A - MarketBeat报道
Saturna Capital Corp Has $63.66 Million Position in Agilent Technologies, Inc. $A - MarketBeat
#Million Position#Agilent Technologies#Capital Corp#Saturna Capital#Million
赛默飞世尔Oncomine Dx靶向检测获FDA批准作为伴随诊断，用于识别适合非小细胞肺癌最新靶向疗法的患者 - 商业资讯
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - Business Wire
#Fisher Scientific#Target Test#Test Receives#Receives FDA#FDA Approval
Sierra Legacy Group增持安捷伦科技股份$A - MarketBeat
Sierra Legacy Group Raises Stake in Agilent Technologies, Inc. $A - MarketBeat
#Agilent Technologies#Legacy Group#Group Raises#Raises Stake#Sierra Legacy
10x Genomics (TXG) 在ASTRA中的角色会改变其在精准肿瘤学领域的竞争优势吗？ - 简沃斯
Will 10x Genomics' (TXG) Role in ASTRA Shift Its Competitive Edge in Precision Oncology? - simplywall.st
#Precision Oncology#ASTRA Shift#Competitive Edge#Genomics'#TXG
为何Lonza集团（普通股）LO3A可能成为2025年最大赢家——关键催化剂与聪明资金动向警示
Why Lonza Group AG (Common Stock) (LO3A) stock could be top winner - 2025 Major Catalysts & Smart Money Movement Alerts - newser.com
#Major Catalysts#Smart Money#Lonza Group#Money Movement#Common Stock
瑞银维持对罗氏控股(RHHVF)的买入评级 - 环球邮报
UBS Sticks to Its Buy Rating for Roche Holding AG (RHHVF) - The Globe and Mail
#Buy Rating#Roche Holding#UBS Sticks#Mail UBS#RHHVF
2025-2035年空间生物学市场分析与预测：Stellaromics、RareCyte及10x Genomics引领创新与融资热潮 - 雅虎财经
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
#Genomics Drive#Biology Market#Market Analysis#Drive Innovation#Funding Momentum
（Modernahù bǎo jiàng 5亿美金 lifeline，瞄准2028年平衡）
Moderna secures $1.5B lifeline as it looks to break even in 2028
#Moderna secures#day event#disease programs#analyst day#invest revenue